Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 31 days later Oct 2026 → Dec 2026
See other at-risk trials from University of Michigan

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 5 entries
    • Primary completion pushed from Oct 2026 to Dec 2026
    • Eligibility criteria shortened, about 10 words
    • Secondary endpoints: details revised at 2 of 2 entries
  2. Primary completion moved earlier from Sep 2027 to Oct 2026v6
  3. Re-verified, no change to tracked fieldsv5
  4. Eligibility criteria expanded, about 9 words
    • Study arms: 4 to 5
    v4
  5. Eligibility criteria expanded, about 27 words
    • Study arms: 3 to 4
    v3
  6. Start date changed from estimate of Sep 2023 to Sep 6, 2023v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Michigan
374 trials monitored
See 22 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.
Trial Details
NCT Number NCT06007404
Lead Sponsor University of Michigan
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Type 2 Diabetes, Insulin Resistance, Obesity, Metabolic Disease, PreDiabetes
Related terms Diabetes Mellitus, Type 2, Insulin Resistance, Metabolic Diseases, Obesity, Prediabetic State
Enrollment 175 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov